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SUMMARY
We evaluated the antifungal activities of amphotericin B, fluconazole, itraconazole and voriconazole in 70 Cryptococcus
neoformans strains obtained from cerebrospinal fluid from AIDS patients and 40 C. neoformans strains isolated from the environment.
Four clinical isolates were identified as C. neoformans var. gattii. The susceptibility test was done using a broth microdilution
method according to NCCLS M27-A2. Range minimal inhibitory concentrations (MICs) for C. neoformans clinical isolates were
0.06-1.0 µg/mL for amphotericin B, 0.125-8 µg/mL for fluconazole, 0.03-0.5 µg/mL for itraconazole and 0.03-0.25 µg/mL for
voriconazole. C. neoformans environmental isolates showed range MICs 0.015-0.125 µg/mL, 0.25-2.0 µg/mL, 0.007-0.125 µg/mL
and 0.03-0.25 µg/mL for amphotericin B, fluconazole, itraconazole and voriconazole respectively. The MICs results obtained
from clinical and environmental isolates showed similar pattern of susceptibility and no resistance has been found in our isolates.
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INTRODUCTION
Cryptococcus neoformans is an encapsulated, spherical yeast of
which three varieties are recognized, C. neoformans var. neoformans
(serotypes D and AD), C. neoformans var. grubii (serotype A) and C.
neoformans var. gattii (serotypes B and C). The neoformans and grubii
varieties have a worldwide distribution, and it is associated with soil
contaminated with bird droppings. C. neoformans var. neoformans is
generally responsible for cryptococcosis in immunocompromised
patients, particularly in HIV infected individuals1,6,22,24. C. neoformans
var. gattii is geographically restricted to tropical and subtropical
climates, and it is most commonly found in association with Eucalyptus
camaldulensis and E. tereticornis trees5,13,16. This variety causes
infection in apparently healthy hosts and it is considered as a true
pathogen3,11,27. C. neoformans infection occurs after inhalation from
environmental sources, of yeast cells into the lung, with hematogenous
dissemination to the central nervous system, where causes cryptococcal
meningitis, the most common and serious cryptococcal disease
manifestation26.
Until now, the currently accepted therapies for cryptococcosis are
limited to amphotericin B, 5-fluorocytosine and fluconazole4. However,
the treatment drugs for cryptococcosis are not satisfactory, because of
their toxicity, their limited ability to clear infections completely,
accompanied by the development of resistance in fungi1. Thereby,
methods for testing the antifungal susceptibility of C. neoformans
should become important tools for the selection and monitoring of
appropriate antifungal drugs for the treatment and prophylaxis of
cryptococcal infections.
By the fact that there are few comparative studies carried out on
antifungal susceptibilities from environmental and clinical C.
neoformans isolates, the purpose of this investigation was to verify the
in vitro susceptibility of 110 C. neoformans isolates (70 clinical and
40 environmental) towards four antifungal agents, including
fluconazole, itraconazole, voriconazole and amphotericin B, using the
broth microdilution method19.
MATERIALS AND METHODS
1. Organisms: A total of 110 C. neoformans isolates were included
in this study. They comprised 70 clinical strains isolated from
cerebrospinal fluid from AIDS patients and 40 environmental isolates
from pigeon excreta and from Eucalyptus trees, originated from Goiânia
city, located in Midwest region of Brazil. C. neoformans was identified
by colonial and cellular morphologies and physiological and
biochemical characteristics10. The varieties were determined in
canavanine-glycine-bromothymol blue agar (CGB)12. These isolates
were stored at 4 ºC on Sabouraud dextrose agar slants (Difco) and
subcultured 72 h prior the test.
2. Antifungal susceptibility testing: Standard broth microdilution
method recommended by the NCCLS M27-A212 was used.
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2.1. Antifungal agents: Amphotericin B (Fungizone, Squibb,
USA), itraconazole (Jansen Pharmaceuticals, Beerse, Belgium) and
voriconazole (Pfizer Pharmaceutical Group) were dissolved in dimethyl
sulfoxide, and fluconazole (Pfizer International, New York, USA) was
dissolved in distilled water. Further dilutions of each antifungal agent
were prepared with RPMI 1640 medium (Sigma) containing L-
glutamine without sodium bicarbonate, and buffered to a pH 7.0 with
0.165M morpholinepropanesulfonic acid (MOPS) (Sigma).
2.2. Inoculum: The suspension of yeast from 48-h-old cultures
was prepared in sterile saline (0.85%) adjusted with a
spectrophotometer to a cell density of 0.5 McFarland standard at a
wavelength of 530 nm. This suspension was diluted at 1:50 followed
by a 1:20 dilution in RPMI 1640 in order to obtain a final concentration
of 1 x 103 to 5 x 103 CFU/mL.
2.3. Susceptibility testing: Microtitre plates were covered with
100 µL of different concentrations of the antifungal agents and added
with 100 µL of the yeast suspension. A final inoculum of 0.5 x 103 to
2.5 x 103 CFU/mL and the final concentrations of the antifungal agents
ranged from 0.03 to 64 µg/mL for fluconazole and 0.007 to 16 µg/mL
for itraconazole, voriconazole and amphotericin B. These plates were
incubated at 35 ºC and read after 72 hours. The MIC end points were
defined for amphotericin B as the lowest concentration of drug which
resulted in a complete inhibition of visible growth, while for the three
azoles were defined as the lowest concentration of drug that produced
a 80% reduction in fungal growth compared to that one of drug-free
growth control. All susceptibility tests were performed twice by each
antifungal agent.
3. Quality control: Quality control organism Candida parapsilosis
ATCC 22019 was included on each day of testing to check the accuracy
of the drug dilutions and the reproducibility of the results. The purity
and viability of all tested organisms were checked subculturing the
inoculum suspension in Sabouraud dextrose agar (Difco).
As the breakpoint susceptibility values have not yet been proposed
by the NCCLS M27-A212 for C. neoformans, the resistance to antifungal
agents considered for fluconazole was ≥ 64 µg/mL, for itraconazole and
voriconazole ≥ 1 µg/mL and ≥ 2 µg/mL for amphotericin B14,17,20, 24.
RESULTS
From the 70 clinical isolates obtained from AIDS patients
cerebrospinal fluid, 66 were identified as C. neoformans var.
neoformans and four as C. neoformans var. gattii. All environmental
isolates were identified as C. neoformans var. neoformans.
All C. neoformans isolates were susceptible to amphotericin B,
fluconazole, itraconazole and voriconazole. However, MIC values of
the clinical isolates for all tested antifungal drugs were higher than for
the environmental isolates. The analysis of MIC50 and MIC90 values
showed that the major difference between clinical and environmental
isolates was verified for amphotericin B. MIC50 values for clinical isolates
were fourfold higher than that for environmental isolates for this drug.
The MIC ranges and MIC required to inhibit 50% and 90% for
amphotericin B, fluconazole, itraconazole and voriconazole are
summarized in Table 1. The MICs for organism control C. parapsilosis
ATCC 22019 tested in the experiments were consistently in agreement
with those from the NCCLS reference results.
The MICs of amphotericin B, itraconazole and voriconazole for four
clinical isolates of C. neoformans var. gattii showed low values, while
for fluconazole the range MICs was 4-8 µg/mL. The results of MIC
values for each C. neoformans var. gattii are presented in Table 2.
DISCUSSION
Although cryptococcosis is the sixth most common opportunistic
infection among HIV positive patients in Brazil8, little is known of
this disease in Goiânia City, State of Goiás.
The varieties in this study were determined in CGB medium and
C. neoformans var. neoformans predominated in isolates from
environmental and clinical sources followed by C. neoformans var.
gattii. Previous reports has shown C. neoformans var. neoformans as
prevalent in Brazil7,9,21. Interestingly, a number of epidemiological
studies have demonstrated that almost all cryptococcal infections in
AIDS patients are due to the neoformans variety, that has long been
known to be associated with pigeon excreta6,22. Limited exposure of
HIV-infected patients to C. neoformans var. gattii can result in fewer
infections by this variety. In spite of seeking C. neoformans var. gattii
in environment, including eucalyptus trees, we are unable to isolate it.
The in vitro susceptibilities of C. neoformans strains to different
antifungal drugs have been studied by a number of investigators2,15,18,24.
However, there is few comparison of MIC data between clinical and
environmental isolates. Our results showed similarity in the pattern of
susceptibility in concern to the origin of the isolates (clinical or
environmental). Testing antifungal susceptibility for environmental
isolates may serve to evaluate the patterns of susceptibility of clinical
isolates from the same geographic areas. The exposure to C. neoformans
isolates could be associated with the infection risk in a given population.
In spite of fluconazole being the drug that commands maintenance
treatment protocols for AIDS patients, in the present study, the highest
MICs were detected for this drug. Other reports have demonstrated
lower in vitro activity of fluconazole compared with other azoles4,23.
SOARES et al.24 by using the EUCAST broth microdilution method,
obtained C. neoformans isolates from pigeons resistant to fluconazole.
The lowest activity in vitro and the highest one in vivo can be explained
by plasmatic levels of fluconazole that can be higher that other azoles
as itraconazole18.
Although all the tested isolates have been susceptible to fluconazole,
C. neoformans var. gattii isolates exhibited relatively higher MIC values
than C. neoformans var. neoformans. Interestingly, infections due to
C. neoformans var. gattii often require prolonged antifungal therapy24.
As it was seen in Tables 1 and 2, our MIC ranges obtained for
amphotericin B allow us to conclude that the studied clinical and
environmental isolates are susceptible to this drug. Amphotericin B is
considered the treatment of choice for the initial stages of therapy and
it is known that reports about amphotericin B resistance C. neoformans
isolates are scarce.
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Besides fluconazole, products currently available, voriconazole and
itraconazole, appear to represent interesting alternatives for AIDS
patients maintenance treatment. Voriconazole and itraconazole
demonstrate excellent in vitro activity against C. neoformans23. As
showed in Table 1, all strains were highly sensitive to two azoles; 90%
of the isolates showed a minimum inhibitory concentration of 0.125
µg/mL for the two antifungal agents.
In conclusion although no resistance has been found in our isolates,
we continue paying attention to the emerging resistance to azoles,
mainly fluconazole which should be searched, due to the widespread
use of fluconazole as primary prophylaxis in AIDS patients.
RESUMO
Suscetibilidade antifúngica de isolados clínicos e ambientais de
Cryptococcus neoformans na cidade de Goiânia, Goiás, Brasil
A atividade antifúngica de anfotericina B, fluconazol, itraconazol
e voriconazol foi avaliada em 70 amostras de Cryptococcus neoformans
isoladas de liquido céfalo raquidiano (LCR) de pacientes com AIDS e
em 40 amostras de C. neoformans obtidas do meio ambiente. Dentre
os isolados 66 foram identificados como C. neoformans var. neoformans
e quatro isolados clínicos, como C. neoformans var. gattii. Para a
realização dos testes de suscetibilidade foi utilizado o método de
microdiluição em meio líquido segundo o NCCLS M27-A2. As
concentrações inibitórias mínimas (CIMs) para os isolados clínicos
variaram de 0,06-1,0 µg/mL para anfotericina B, 0,125-8 µg/mL para
fluconazol, 0,03-0,5 µg/mL para itraconazol e 0,03-0,25 µg/mL para
voriconazol, enquanto que para as amostras ambientais de C.
neoformans as concentrações inibitórias variaram de 0,015-0,125 µg/
mL, 0,25-2,0 µg/mL, 0,007-0,125 µg/mL e 0,03-0,25 µg/mL para
anfotericina B, fluconazol, itraconazol e voriconazol, respectivamente.
Os resultados das concentrações inibitórias mínimas obtidas para os
isolados clínicos e ambientais mostraram semelhança com relação ao
perfil de suscetibilidade, não tendo sido encontrados isolados resistentes
a nenhum dos antifúngicos, levando-se em consideração a metodologia
e critério de interpretação estudados.
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